艾伯维公司 ABBV 深 沪
等待开盘 02-07 09:30:00 美东时间
223.09
+4.390
+2.01%
华盛通- 最 高237.04
- 今 开218.98
- 成交量 149.72万股
- 最 低 204.27
- 昨 收 218.70
- 总市值 3.94亿
- 52周最高 237.04
- 市盈率 静 34.57
- 换手率 84.73%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 0.02亿
- 历史最高 237.04
- 量 比 0.94
- 振 幅 14.98%
- 历史最低 0.00
- 每 手 1
- 风险率 17.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth
AbbVie beat Q4 earnings and sales estimates, driven by strong Skyrizi and Rinvoq growth. The drugmaker raised its 2026 outlook despite falling Humira sales and mixed results in aesthetics.
02-05 01:38
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs
UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.
01-29 01:07
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
01-28 18:51
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement.
01-26 19:01
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-16 01:35
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines
AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secure tariff relief.
01-13 21:09
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01-12 18:47
AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial
AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports
01-09 02:41
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
